Failure of apoptosis and activation on NFκB by celecoxib and aspirin in lung cancer cell lines

Oncology Reports

Volumn 17, Issue 4, 2007, Pages 823-828

  Gradilone, Angela ^a   Silvestri, Ida ^a   Scarpa, Susanna ^a   Morrone, Stefania ^a   Gandini, Orietta ^a   Pulcinelli, Fabio M ^a   Gianni, Walter ^b   Frati, Luigi ^a   Aglianò, Anna Maria ^a   Gazzaniga, Paola ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b INRCA   (Italy)

Author keywords

Apoptosis; Aspirin; Celecoxib; Chemoprevention; Lung cancer; NF B

Indexed keywords

ACETYLSALICYLIC ACID; BIRC5 PROTEIN, HUMAN; CELECOXIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN BCL 2; PROTEIN BCL X; PYRAZOLE DERIVATIVE; SULFONAMIDE; TRANSCRIPTION FACTOR RELA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; TUMOR CELL LINE; UPREGULATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; ASPIRIN; BCL-X PROTEIN; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOOXYGENASE INHIBITORS; HUMANS; LUNG NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZOLES; SULFONAMIDES; TRANSCRIPTION FACTOR RELA; UP-REGULATION;

EID: 34249942270     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.4.823     Document Type: Article

References (31)

1. Diperna CA, Bart RD, Sievers EM, Ma Y, Starnes VA and Bremner RM: Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma. J Thorac Cardiovasc Surg 126: 1129-1133, 2003. (Pubitemid 37305701)
2. Sandler AB and Dubinett SM: COX-2 inhibition and lung cancer. Semin Oncol 31: 45-52, 2004. (Pubitemid 38879414)
3. Brown JR and DuBois RN: Cyclooxygenase as a target in lung cancer: Clin Cancer Res 10: S4266-S4269, 2004.
4. Baron JA, Cole BF, Sandler RS, et al : A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348: 891-899, 2003. (Pubitemid 36297997)
5. Giovannucci E, Egan KM, Hunter DJ, et al: Aspirin and the risk of colorectal cancer in women. N Engl J Med 333: 609-614, 1995.
6. Moysich KB, Menezes RJ, Ronsani A, et al: Regular aspirin use and lung cancer risk. BMC Cancer 2: 31, 2002.
7. Cook NR, Lee IM, Gaziano JM, et al: Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294: 47-55, 2005. (Pubitemid 41002838)
8. Gasparini G, Meo S, Comella G, et al: The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates. Cancer J 11: 209-216, 2005. (Pubitemid 44698809)
9. Nugent FW, Mertens WC, Graziano S, et al : Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced nonsmall cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial. Lung Cancer 48: 267-273, 2005.
10. Agarwal B, Swaroop P, Protiva P, Raj SV, Shirin H and Holt PR: Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells. Apoptosis 8: 649-654, 2003. (Pubitemid 37411749)
11. El-Rayes BF, Ali S, Sarkar FH and Philip PA: Cyclooxygenase-2- dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol Cancer Ther 3: 1421-1426, 2004. (Pubitemid 39562587)
12. Maier TJ, Schilling K, Schmidt R, Geisslinger G and Grosch S: Cyclooxygenase-2 (COX-2)-dependent and -independent anti-carcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 67: 1469-1478, 2004. (Pubitemid 38388209)
13. Tegeder I, Niederberger E, Israr E, et al : Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen. FASEB J 15: 2-4, 2001.
14. Yamamoto Y, Yin MJ, Lin KM and Gaynor RB: Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 274: 27307-27314, 1999.
15. Yin MJ, Yamamoto Y and Gaynor RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396: 77-80, 1998. (Pubitemid 28520452)
16. Kopp E and Ghosh S: Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265: 956-959, 1994.
17. Cuesta E, Boada J, Perales JC, Roig T and Bermudez J: Aspirin inhibits NF-kappaB activation in a glycolysis-depleted lung epithelial cell line. Eur J Pharmacol 517: 158-164, 2005. (Pubitemid 40977890)
18. Sclabas GM, Uwagawa T, Schmidt C, et al : Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer 103: 2485-2490, 2005. (Pubitemid 40800526)
19. Shishodia S and Aggarwal BB: Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. Cancer Res 64: 5004-5012, 2004. (Pubitemid 38924549)
20. Subhashini J, Mahipal SV and Reddanna P: Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro. Cancer Lett 224: 31-43, 2005. (Pubitemid 40720365)
21. Niederberger E, Tegeder I, Vetter G, et al: Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. FASEB J 15: 1622-1624, 2001.
22. Kim SH, Song SH and Kim SG: Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target. J Cancer Res Clin Oncol 130: 551-560, 2004.
23. Stark LA, Din FV, Zwacka RM and Dunlop MG: Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J 15: 1273-1275, 2001.
24. Din FV, Dunlop MG and Stark LA: Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br J Cancer 91: 381-388, 2004. (Pubitemid 39037087)
25. Gu Q, Wang JD, Xia HH, et al: Activation of the caspase-8/Bid and Bax pathways in aspirin-induced apoptosis in gastric cancer. Carcinogenesis 26: 541-546, 2005. (Pubitemid 41214142)
26. Redlak MJ, Power JJ and Miller TA: Role of mitochondria in aspirin-induced apoptosis in human gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol 289: G731-G738, 2005. (Pubitemid 41377180)
27. Arico S, Pattingre S, Bauvy C, et al: Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 277: 27613-27621, 2002. (Pubitemid 34966703)
28. Kucab JE, Lee C, Chen CS, et al: Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res 7: R796-R807, 2005.
29. Jendrossek V, Handrick R and Belka C: Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J 17: 1547-1549, 2003.
30. Liu X, Yue P, Zhou Z and Sun SY: Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 96: 1769-1780, 2004. (Pubitemid 39654571)
31. Sun SY, Schroeder CP, Yue P, Lotan D, Hong WK and Lotan R: Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations. Cancer Biol Ther 4: 407-413, 2005. (Pubitemid 41351257)